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Objectives: The purpose of this study was to investigate the effects of gene transfection of endothelial cells with vascular
endothelial growth factor (VEGF) on re-endothelialization and inhibiting in-stent restenosis.
Methods: Stents coated with human umbilical vein endothelial cells (HUVECs) transfected with VEGF121 were studied
both in vitro and in vivo. In vitro studies were performed using a homemade extracorporeal circulation system. In vivo
studies were performed using the rabbit abdominal aorta model.
Results: In vitro studies confirmed that VEGF121-transfected cells adhered on the surface of stainless steel stents with over
90% of the surface covered within 24 hours of seeding. In vivo results showed that VEGF121-transfected HUVECs-coated
stents were covered with seeding cells after implanting, and almost completely covered with cells after stent implantation
for 1 week. In contrast, the non-endothelialized areas of bare metal stents and glutin/poly-L-lysine-coated stents were
covered at 4 weeks, and the monolayers of cells were not observed, but fragile neointima was found on the surface. After
12 weeks, VEGF121-transfected HUVECs-coated stents significantly reduced the neointima area (0.78 0.03 mm2) and
stenosis (15.69  2.61%) as compared with those for bare metal stents (neointima area  2.26  0.67 mm2; the
percentage of stenosis 47.55 7.10%;P< .01) and glutin/poly-L-lysine-coated stents (neointima area 1.40 0.37
mm2; the percentage of stenosis  31.37  8.18%;P < .01).
Conclusion: In this small animal study,VEGF transfected human endothelial cells, when coated on stainless steel stents, reduce
neointimal hyperplasia, promote endothelialization, and reduce in-stent restenosis. Additional studies with this technology are
necessary to determine its ultimate utility in improving stents performance. (J Vasc Surg 2011;53:461-71.)
Clinical Relevance: This research was based on the clinical complications after stent implantation, especially in-stent
restenosis and late endothelialization. However, here we only carried out the animal experiments.
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pThe integrity and functional activity of the endothelial
monolayer play a crucial role in the prevention of throm-
bosis and in-stent restenosis (ISR). A growing body of
evidence suggests that drugs loaded on drug-eluting stents
could impair the healing process of the injured arterial wall
and lead to delayed re-endothelialization.1,2 The molecular
mechanism is established with cell-cycle regulators3 and
endothelial vasomotor factor in endothelial cells (ECs).4
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doi:10.1016/j.jvs.2010.08.020oreover, drugs may also impair the circulation of endo-
helial progenitor cells for re-endothelialization in vivo.5 It
as been reported that drugs loaded on drug-eluting stents
nhibit proliferation, migration, differentiation, and the
ndothelial nitric oxide synthase (eNOS) production in
uman endothelial progenitor cells.6,7 Therefore, conflu-
nt endothelialization of the stent in vitro before implanta-
ion is proposed as an improved procedure to reduce com-
lications of stent implantation, including thrombosis and
SR.
Vascular endothelial growth factor (VEGF) is a potent
ndothelium-specific angiogenic factor, which promotes
e-endothelialization of the denuded arterial wall.8 Recom-
inant VEGF has been administered in animal models of
rterial injury. Further studies with VEGF-coated stents
ave suggested that increased re-endothelialization reduces
estenosis and inhibits stent thrombosis.9-11 Other endo-
helial mitogens like basic fibroblast growth factor,12
latelet-derived growth factor,13 and eNOS14 have led to
esting the hypothesis that gene therapy-mediated acceler-
tion of endothelial recovery is an alternative strategy for
revention of neointima proliferation.
However, gene therapeutic approach at a targeted site
f arterial injury is commonly limited by a low transfection
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February 2011462 Tang et alefficiency resulting from many factors, such as abrasion of
the endothelial layer.15 Therefore, utilizing transfected
cells may increase the expression of genes and develop an
emerging strategy for arterial gene delivery. In this study,
we used VEGF121-transfected human umbilical vein endo-
thelial cells (HUVECs) as seeding cells on stents and exam-
ined their efficiencies on re-endothelialization in vitro and
suppressing restenosis after implantation in the rabbit ab-
dominal aorta model.
MATERIALS AND METHODS
Culture and identification of human umbilical vein
endothelial cells. HUVECs (a generous gift from Dr
Lushan Liu, Nan Hua University, China) in endothelial
basal media (RPMI 1640; HyClone USA, Logan, Utah)
supplemented with 10% fetal calf serum (FCS; Cambrex
Fig 1. a, A micrograph of human umbilical vein endo
HUVECs detected by immunohistochemistry. c,Western
and -actin: lane 1  nontransfected group; lane 2  pC
d, The real-time reverse transcriptase polymerase chain re
DNA ladder; pCD2-VEGF121-transfected group with R
pCD2-transfected group with RT-PCR (lane 5) and with
and without RT (lane 1). e, High VEGF121 expression
HUVECs, scale bar  100 m.Corp, Charles City, Iowa) and antibiotic/antimycotics so- uution (Gibco Industries Inc, Langley, Okla) were grown to
onfluence in T-75 polystyrene flasks (Becton Dickinson
nd Company, Franklin Lakes, NJ). Cells were cultured in
CO2 incubator (5% CO2) at 37°C. HUVECs were iden-
ified by means of morphology observation (Fig 1, a), and
mmunohistochemistry of CD31 (Platelet-endothelial cell
dhesion molecule-1 [PECAM-1/CD31]) (Fig 1, b; using
nti-human CD31 immunoglobulin G [IgG], Boster,
hina, and goat anti-rabbit IgG Boster, China, as the
econdary antibody).
Stable transfection of VEGF121 in human umbilical
ein endothelial cells. pCD2-VEGF121 (a generous gift
rom Dr Lushan Liu, Nan Hua University, China) were
onstructed by cloning the expression fragment containing
EGF121 (576 bp) into plasmid pCD 3.0 plasmid. HU-
ECs were transfected with VEGF at passage 2 or 3
l cells (HUVECs; bar  200 m). b, CD31-positive
analysis of vascular endothelial growth factor (VEGF)121
ransfected group; lane 3  VEGF121-transfected group.
n (RT-PCR) result of VEGF121mRNA in HUVECs (M:
CR (lane 6) and without radiotherapy (RT; lane 3);
T (lane 2); nontransfected group with RT-PCR (lane 4)
ne-transfected HUVECs and (f) low in nontransfectedthelia
blot
D2 t
actio
T-P
out R
in ge121
sing Lipofectamine 2000 (lipo2000; Invitrogen Corp,
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Volume 53, Number 2 Tang et al 463Carlsbad, Calif) according to our previously reported
methods.16 Briefly, HUVECs were seeded (2  105 cells
per 35-mm well) on plates and grown in RPMI 1640
medium supplemented with 10% FCS for 24 hours. Cells
were then washed three times with phosphate-buffered
saline (PBS; Hyclone, Logan, Utah). A mixture for trans-
fection was prepared by mixing plasmid pCD2-VEGF121
with lipo2000 in medium for 15 to 40 minutes at room
temperature. Transfection was then conducted by incubat-
ing cells in media containing the mixture at 37°C for 4 to 6
hours. The mammalian expression vectors pCD2-VEGF121
can be used for generating stably transfected cell lines using
a selection with geneticin (G418). The neomycin phospho-
transferase (neo) cassette in the backbone of pCD2-
VEGF121 confers resistance to G418. In this study, trans-
fected cells were screened with 700 g/mL of G418
(Amerisco, Solon, Ohio), in which condition non-
transfected cells did not survive. After the screening proce-
dure, transfected cells were cultured in medium containing
G418 (200 g/mL).
Western blot (Fig 1, c), reverse transcription-polymerase
chain reaction (RT-PCR; Fig 1, d) and immunohistochemis-
try (Fig 1, e and f) were used for the assessment of transfection
efficiency. The exact sequences of the primers used for the
VEGF121 RT-PCR were as follows:
5=-GAGTACATCTTC AAG CCATCC TGTGTG-3=
5=-CGCCTCGGCTTGTCACAT TTTTCTTGT-3=
Kit (Beyotime, China) was used to collect cell proteins
and keep identical protein concentration in all samples.
VEGF121 expression in transfected cells was examined by
Western blot, in which the primary polyclonal antibody
against VEGF (Boster, China) and the horseradish peroxi-
dase-signed secondary goat anti-rabbit IgG antibody
(Beyotime, China) were selected, and -actin was used as
internal control. VEGF121 expression was examined also by
immunohistochemistry, in which the primary polyclonal
antibody against VEGF (Boster, China) and the secondary
goat anti-rabbit IgG antibody (Boster, China) were used.
RT-PCR was applied to characterize the gene expression of
VEGF121.
Cell seeding and detecting in vitro. We used 316L
stainless steel stents (1.6 mm in diameter and 18 mm in
length; Beijing AmsinoMedical Co, Ltd, Beijing, China) in
this study. To coat the stent surface with VEGF121-
transfected HUVECs or nontransfected cells, stents were
coated with glutin (0.4%) and poly-lysine (10 g/mL)
using an ultrasonic spraying process, followed by radiation
sterilization with ultraviolet light. Cells were detached from
flasks by mild trypsinization (0.25% trypsin for 2-3 minutes
at 37°C, followed by neutralizing trypsin with FCS). De-
tached cells (105 cells/mL) were resuspended in serum-
free media. The stent was submerged into the medium
containing resuspended cells in an organic glass tube
mounted to a custom-built rotating device for 6 hours of
rotational culture at the speed of 0.4 rpm17 (Fig 2, a),
followed by another 48 hours of static culture. BTo prepare for further characterizations, cells on
he stents were fixed by glutaraldehyde, dehydrated by im-
ersion into ethanol with concentration up to 100%, dried
pecimens with vacuum freeze-drying, mounted dried
pecimens on scanning electron microscope (SEM) speci-
en stub and were sputter coated, and then examined
sing SEM (Fig 2, b and d). Cells were detected by immu-
ofluorescence microscopy (Fig 2, c and e). The primary
ntibody against rabbit VEGF (Boster, China), both the
yanine-labeled secondary goat anti-rabbit IgG antibody
Boster, China) and fluorescein isothiocyanate-labeled sec-
ndary goat anti-rabbit IgG antibody (Beyotime, China)
ere applied for immunofluorescent staining of transfected
ells and non-transfected cells.
A homemade extracorporeal circulation system18 was
sed to simulate the transfer process and to characterize cell
dhesion and cell growth on the modified surface after
tenting in vitro (Fig 3, a). A stent coated with cells was
ounted on a balloon, transported to a gel silica flex
ubing, expanded and perfused at various shear rates (5, 10,
nd 15 dynes/cm2) in the flow system for different lengths
f time to simulate the planting experiments in vivo. To
uantify the amount of cells that remained adherent on the
urface of the stents, cells were first detached and sus-
ended by trypsinization at different time point (0 hours, 6
ours, 12 hours, 24 hours, 48 hours, and 96 hours),
ollowed by methyl thiazolyl-tetrazolium assay (Fig 3, b).
hree independent experiments were performed for each
reatment for statistical analysis.
Animal experiments. Animal housing and surgical
rocedures were followed to conform to the Guide for the
hinese Animal Care and Use Committee standards. All in
ivo procedures were also performed in accordance with
rotocols approved by the Animal Ethics Committee of
hongqing University. Twenty-eight male New Zealand
hite rabbits that were housed in the Animal Laboratory
enter in ChongqingMedical University, China, weighing
rom 1.5 to 2.5 kg were divided into three groups. Group 1
bare metal stents [BMS]; n  9) received bare metal
tents; group 2 (glutin/poly-L-lysine coating stents, GPS,
 9) received glutin/poly-L-lysine coated stents; and
roup 3 (VEGF121-transfected HUVECs-coated stents,
THS; n  10) received VEGF121-transfected HUVECs-
oated stents. Group 3 received an immunological toler-
nce experiment by injecting transfected-cell suspension for
weeks and ensured that the rabbits were healthy without
mmune reactions before the procedure. The cells were
njected intravenously. About 1 105 cells were used in the
njection every day. A blood test was used for immune
eactions. Rabbits were fed with a normal diet. Rabbits
ere anesthetized by administering ketamine (50 mg/kg)
ntramuscularly and sodium pentobarbital (30 mg/kg) in-
ravenously. A 5F introducer sheath was positioned in the
ight femoral artery under surgical exposure. Heparin so-
ium (200 IU/kg) was intra-arterially injected. All cathe-
ers were subsequently introduced through this sheath and
dvanced to the external iliac artery through a 0.014-inch
alanceMiddleWeight guidewire (Guidant Corp, St. Paul,
1
a
g
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February 2011464 Tang et alMinn). Baseline angiograms of the external iliac arteries
were obtained for each rabbit. Abdominal aorta injury
was performed using an angioplasty balloon catheter
Fig 2. Non-transfected (b and c) and vascular endoth
umbilical vein endothelial cells (HUVECs) were seeded o
device (a) and another 48 hours of static culture. Cell adh
electron microscope (SEM; b and d), and VEGF expre
photos demonstrated that 90% cell coverage on the
HUVECs (b bar  50 m, c bar  100 m, d bar  10(Clearstream, Ireland) at 10 atm for three times in the f0-second interval manner at the same location. With
ngiography, prepared stents filled with bare metal stent,
lutin/poly-L-lysine-coated stents, and VEGF -trans-
growth factor (VEGF)121-transfected (d and e) human
stents, followed by 6 hours of rotational culture by the
s on the surface of the stents were detected by scanning
was detected by immunofluorescence (c and e). These
t surface was accomplished with VEGF121-transfected
, e bar  100 m).elial
n the
esion
ssion
sten121
ected HUVECs-coated stents were deployed in the infrare-
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Volume 53, Number 2 Tang et al 465nal abdominal aorta. The abdominal aorta was injured with
an angioplasty balloon (diameter 3 mm, length 3 cm). The
position of the stent was located at the same position of the
balloon injury, which could be located by the guidewire
(there are two radiograph opacity sites on the guidewire).
Stents were dilated at 10 atm and taken to ensure that no
branches were present in the stent segment. At the level of
the balloon dilatation, the diameter of the aorta was 2.8 to
3.0 mm, and the expansion ratio of the aorta was between
1.2 and 1.3. Predeployment and postdeployment digital
subtraction angiography was recorded. Rabbits were fed a
normal diet after the intervention.
One rabbit was killed immediately for the excision of
the aortic segment containing the stent after stent plant-
ing to test the cell’s reservation. The other rabbits were
killed at week 1, week 4, and week 12 time points (n 3,
at each time point of each group). Aortic specimens were
excised transversely into two parts. One was fixed in 4%
paraformaldehyde and then embedded in light-cured
resin through toluidine blue stain for pathology organi-
zation analysis. The other was fixed in 0.25% glutaralde-
hyde for 12 to 16 hours for SEM and morphologic
Fig 3. Cell adhesion and growth on the stent surface
system (a) after expanding and flushing at 5 dyn/cm2
hours showed that a detectable amount of cells was flus
stents is time-dependent changes after expanding and
dyn/cm2 (b). A vascular endothelial growth factor (VE
(HUVECs)-coated stent was implanted into the rabb
(SEM) detection after 6 hours to detect the cell reser
surface of stents after implanting (d).analysis of intima surface. oMorphometric analysis was performed with a comput-
rized digital image analysis system by an independent
bserver blinded to the study groups. Histomorphometric
nalysis of each section included vessel area (mm2), internal
lastic lamina (IEL) area (mm2), lumen area (mm2), neo-
ntima area (mm2), and the neointima thickness (mm) by
mageTool (version 2.0; UTHSCSA). The percentage of
tenosis was calculated using the following equation:19
1 (IEL area neointima area)IEL area  100.
Statistical analysis. All statistical analyses were per-
ormed with SPSS (version 11.0; SPSS Inc, Chicago, Ill).
ll data are presented as mean  SD. Comparisons be-
ween group means were determined by t test. Probability
alues of P .05 was considered as significant, and P .01
as highly significant.
ESULTS
Identification of HUVECs. HUVECs were identi-
ed in terms of the morphology (Fig 1, a), immunohisto-
hemistry of CD31 (Fig 1, b). Fig 1, a shows that the shape
examined by a homemade extracorporeal circulation
hours, 6 hours, 12 hours, 24 hours, 48 hours, and 96
way from the stents. Cell growth on the surface of the
ng at shear stress of 5 dyn/cm2, 10 dyn/cm2, and 15
21-transfected human umbilical vein endothelial cells
ery and taken out for scanning electron microscope
n in vivo (c and d). Numerable cells adhered on thewas
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February 2011466 Tang et alplates. A positive immunohistochemistry staining of CD31
was found, as indicated by cell-edged brown circles repre-
senting the expression of CD31 in cellular membranes.
Therefore, the characteristics of cultured cells were consis-
tent with those of HUVECs.
Transfection with VEGF121 to HUVECs. After
the transfection with VEGF121 to HUVECs, transfected
cells were observed under an inverted microscope. Based
on the results of Western blot analysis, the expression of
VEGF in the VEGF121-transfected group was higher than
that in the nontransfected group and pCD2 transfected
group (Fig 1, c). Results from RT-PCR clearly showed that
the gene of VEGF121 was detected in transfected HUVECs
(Fig 1, d). Immunohistochemistry studies showed signifi-
cantly increased expression of VEGF in transfected cells (Fig
1, f); whereas normal rounded nontransfected cells exhibited
Fig 4. Scanning electron microscope (SEM) images of
coated stents (GPS, Fig B/b), and vascular endothelial
endothelial cells (HUVECs)-coated stent (VTHS, Fig
demonstrated a complete endothelial coverage from thelittle expression of VEGF (Fig 1, e). nTransfection with VEGF121 promoted cell growth
nd adhesion on stents in vitro. VEGF121-transfected
UVECs and nontransfected HUVECs were seeded on
tents and were observed by SEM. Although seeding of
ransfected cells achieved a high fraction of cell coverage
n the stent surface, non-transfected cells exhibited a
ounded morphology and seemed low cell coverage on the
tent in the same culture condition (Fig 2, b and d). Results
rom immunofluorescence microscopy also demonstrated
hat 90% cell coverage on the stent surface was accom-
lished with VEGF121-transfected HUVECs (Fig 2, c and
), whereas using nontransfected cells exhibits less cell
overage on stents. Cell adhesions on the surface of the
tents were also detected by fluorescence microscopy of
EGF. Red fluorescence indicated that the expression of
EGF in gene-transfected cells was higher than that in
are metal stents (BMS, Fig A/a), glutin/poly-L-lysine-
th factor (VEGF)121-transfected human umbilical vein
c) after implantation for 1 week. The VTHS group
eek (A, B, and C, 50; a and b, 1k, c, 500).the b
grow
C/ontransfected cells (Fig 2, c and e). Due to the low cell
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Volume 53, Number 2 Tang et al 467coverage on the stent surface accomplished with nontrans-
fected cells, we chose to focus on VEGF121-transfected
HUVECs for further in vitro study using the flow system
and in vivo study using the rabbit abdominal aorta
model.
The stents coated with transfected cells were expanded
by a balloon in vitro and subjected to flow shear stresses at
5, 10, and 15 dyn/cm2 in the flow system for various
durations. In this experiment, the amount of live cells was
quantified by methyl thiazolyl-tetrazolium assay. Results
from experiments with stents studied in the flow system
showed that a detectable amount of cells was flushed off
from the stents in the first 6 hours, which increased with
increasing shear stress. After 6 hours, the population of cells
increased, and cell proliferation was observed at three levels
of different shear stresses. A more rapid cell proliferation
was observed at 5 dyn/cm2 of shear stress, implicating the
role of shear stress in both adhesion and growth of cells on
Fig 5. Scanning electronmicroscope (SEM) images of the
stents (GPS, FigB/b), vascular endothelial growth factor (V
(HUVECs)-coated stent (VTHS, Fig C/c) after implantatthe stent surface (Fig 3, b). wVEGF121-transfected HUVECs in rabbit abdomi-
al aortamodel. Three rabbits died because the vessel was
roken before the stent. One died during the procedure of
tent implantation. Twenty-eight stents (9 BMS, 9 GPS,
nd 10 VTHS) were deployed in the abdominal arteries of
abbits. All rabbits survived for the entire study period
after 1 week, 4 weeks, and 12 weeks). Rabbits were then
illed for histomorphometric, histopathologic analysis, and
he evaluation of endothelial regeneration. Angiograms
btained immediately after stent implantation and before
uthanasia showed that all deployment procedures were
uccessful and that all the stents were dilated. A VTHS was
mplanted into rabbit artery and taken out for SEM
etection after 6 hours to detect the cell reservation in
ivo (Fig 3, c and d). Numerable cells adhered on the
urface of stents after implanting (Fig 3, d). Figs 4-6
hows the re-endothelialization areas on the stents. Re-
ults showed that VTHS was almost completely covered
metal stents (BMS, FigA/a), glutin/poly-L-lysine-coated
121-transfected human umbilical vein endothelial cells, and
r 4 weeks (A, B, and C, 50; a, b, and c, 1k).bare
EGF)ith cells after stent implantation for 1 week (Fig 4,C/c),
JOURNAL OF VASCULAR SURGERY
February 2011468 Tang et alFig 6. Scanning electronmicroscope (SEM) images of the baremetal stents (BMS, FigA/a), glutin/poly-L-lysine-coated
stents (GPS, FigB/b), vascular endothelial growth factor (VEGF) -transfected human umbilical vein endothelial cells, and121
(HUVECs)-coated stent (VTHS, Fig C/c) after implantation for 12 weeks (A, B, and C, 50; a, b, and c, 1k).
Dw
i
n
a
p
i
f
t
r
i
P
s
s
f
t
a
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 2 Tang et al 469where large numbers of platelets and red cells covering the
non-endothelialized areas of BMS (Fig 4, A/a) and GPS
(Fig 4, B/b) at 1 week. BMS (Fig 5, A/a) and GPS (Fig 5,
B/b) were covered at 4 weeks, and the surface of HUVECs-
coated stent was almost the same as the surface at 1 week
(Fig 5,C/c). The morphology of newly covered cells on the
surface of VTHS had little difference with various implan-
tation periods. After implantation of 12 weeks, a mono-
layer of cells was not found (Fig 6, A/a), and fragile
neointima was found on the surface of GPS (Fig 6, B/b)
and BMS (Fig 6, C/c). Fig 7 shows representative arterial
cross-sections from different treatment groups. The
quantitative histomorphometric data for each of the
stent groups are summarized in the Table. After 12
weeks, VTHS significantly reduced the neointima area
(0.78  0.03 mm2) and stenosis (15.69  2.61%) as
compared with those for BMS (neointima area  2.26 
0.67 mm2 and the percentage of stenosis  47.55 
7.10%) and GPS (neointima area  1.40  0.37 mm2
Fig 7. Representative sections of arteries at the sites of s
c1, bar  500 m), 4 weeks (a2, b2, c2,, bar  500 m)
blue stain. (a1), (a2) and (a3) bare metal stent (BMS) g
group; (c1), (c2) and (c3)VEGF121-transfected human um
Black arrows indicate the neointima.and the percentage of stenosis 31.37 8.18%) in vivo. iISCUSSION
Re-endothelialization had been reported to occur
ithin 4 weeks in rabbit external iliac vessels after stent
mplantation.20,21 However, this process may require sig-
ificantly longer time (12 weeks) in humans. VEGF121
ccelerates endothelial repair by stimulating migration and
roliferation of ECs. Results reported by Hedman et al22
ndicated that catheter-mediated intracoronary gene trans-
er of VEGFwas safe and well tolerated to prevent ISR. The
reatment did not affect the incidence of postangioplasty
estenosis, whereas a significant improvement was observed
n myocardial perfusion in the VEGF-Adv-treated patients.
reclinical proangiogenic VEGF studies and anti-VEGF
tudies have shown that the disturbance of vascular homeo-
tasis by blocking VEGF-A may lead to endothelial dys-
unction and adverse vascular effects.23
Although VEGF therapy has been proven to be of
remendous potential, the preclinical results obtained in
nimal experiments have not yet been translated into clin-
truts demonstrating neointima growth at 1 week (a1, b1,
12 weeks (a3, b3, c3, bar  500 m) through toluidine
; (b1), (b2) and (b3) glutin/poly-L-lysine-coated stent
l vein endothelial cells (HUVECs) stent (VTHS) group.tent s
, and
roup
bilicacal success. The challenge focuses on the complication
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February 2011470 Tang et alcaused by the carrying agent. Therefore, ECs were pro-
posed here as the perfect carrying agent ofVEGF in terms of
their histocompatibility and blood compatibility. In this
study, HUVECs transfected with VEGF were found
to promote endothelialization in vitro, whereas non-
transfectedECs seemed to have low recovery ability, and their
growth rate dramatically dropped as compared to that of
transfected cells. As supported by results from our immu-
nohistochemistry study of VEGF, VEGF121-transfected
cells expressed VEGF protein, which may maintain local
concentration of the growth factor around the stent,
thereby enhancing the healing process.
On the other hand, the existence of VEGF may pro-
mote the immunosuppression.24 Injecting and implanting
transfected cells improved the VEGF level in the serum,
which may play an important role in the cell retention on
the stent surface. Hence, nontransfected HUVECs were
not used for further studies in the flow system and animal
experiments, due to their slow growth, low surface cover-
age, and immunological rejection. In this study, we seeded
VEGF121-transfected HUVECs on the surface of metal
stents before implantation. There are two preponderances
for implantation of VEGF121-transfected HUVECs-coated
stents: VEGF expression through stable transfection pro-
motes proliferation of ECs and shortens the duration of the
cell seeding and coating cells protects vessel wall integrity
from the metal stent after implantation.
The rotational culture model was used in this study.
The rotational ECs seeding had been used in several stud-
ies25,26 because many three-dimensional cell material con-
structs favor dynamic culture conditions. Dynamic culture
conditions are frequently applied for cell seeding in the
vascular grafts such as polymer materials.27 However, they
are rarely used in endovascular stents. In this study, a
rotational device was used for cell seeding on stents and a
high surface coverage and cell proliferation of VEGF121-
transfected HUVECs on both the inner and outer surfaces
of stents were achieved.
However, the role of VEGF in neointima formation
and ISR remains to be fully elucidated.28,29 For example,
the presence of transfected HUVECs and the VEGF ex-
pression must be traced after stent deployment at different
time courses. Chromosome analyses are required for iden-
tifying if HUVECs are allogenic cells for rabbits or not. The
Table. Histomorphometric measurements
Experimental
group
Vessel area
(mm2)
Lumen area
(mm2)
IEL area
(mm2)
BMS 5.83  0.16 2.66  0.30 5.08  0.2
GPS 5.30  0.20 3.06  0.39 4.46  0.1
VTHS 5.50  0.18a 4.78  0.13a,b 4.97  0.1
BMS, Bare metal stents;GPS, glutin/poly-L-lysine coating stents; IEL, intern
umbilical vein endothelial cells-coated stents.
aVTHS vs BMS, P  .01.
bVTHS vs GPS, P  .01.
cVTHS vs GPS, P  .05.results thus obtained would identify and verify whetheroated HUVEC disappeared or not and which cells are
roliferated and migrated to the area of implantation. Such
nformation will help elucidate the mechanism of how
oating VEGF-transfected human endothelial cells on
tents promotes re-endothelization and inhibits ISR.
In conclusion, after 12 weeks of stent implantation,
EGF121-transfected HUVECs-coated stents showed re-
uced neointima area and stenosis as compared with bare
etal stents and glutin/poly-L-lysine-coated stents. Our
esults, collected from both in vitro and in vivo studies,
uggested that VEGF121-transfected HUVECs-coated
tents could be a new therapeutic strategy to reduce
n-stent neointima formation because no evidence of either
ystemic or local adverse effects was observed in rabbits.More
tudies are required to validate this therapeutic strategy, for
xample, the examination of possibly long-term complica-
ions introduced by transfected cells in vivo.
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